Mitostem, Inc. was founded in 2008 with the goal to drive innovation, and accelerate the scientific breakthroughs that will advance Stem Cell research and the field of Regenerative Medicine.
MitoStem focuses on developing and commercializing novel technologies to advance stem cell research and the field of regenerative medicine. Stem cells have the ability to reproduce themselves (self-renew) or differentiate into each of the cell types found in the body. In the future, Pluripotent Stem Cells (PSC) will be able to replace diseased and damaged organs. Until recently, only stem cells derived from embryos were pluripotent. However, controversies are associated with using cells from embryos, and they can only be used for study of diseases that are diagnosed during assisted reproduction procedures (in vitro fertilization).
Mitostem is working to develop and commercialize a protein transduction technology, which will make the generation of iPSC's more practical, simple and affordable. We have obtained preliminary data that demonstrate the feasibility and promise of our technology, and are currently working through a $200k phase I SBIR from the National Institue of Health for process optimization.
Mitostem is located in TechTown, Wayne State University's business incubator. It is housed within the Great Lakes Stem Cell Commercialization Center in the TechOne building, which is a dedicated incubator for biotech firms possesing those capabilities necessary to either conduct, or aid others in conducting stem cell based research.